|
|
Other links at Articles > Cardiology |
| 2. |
New Data Look Promising for Rivaroxaban
|
|
|
Two phase 3 trials with the new oral anticoagulant rivaroxaban suggest it is more effective than enoxaparin in preventing venous thromboembolism in patients undergoing major orthopedic surgery. Heartwire
|
| 3. |
BART Closes the Book on Aprotinin
|
|
|
Results from the trial -- halted last year due to safety concerns -- clearly point to increased deaths in high-risk coronary artery bypass graft patients randomized to aprotinin. Medscape Medical News
|
| 5. |
Layoffs for Schering-Plough, but One Large Insurer Still Backs Ezetimibe
|
|
|
Schering-Plough Corporation announced that 5500 employees are being laid off, with sales and marketing to be hit first. In other news, the company released more emails between Kastelein and executives, arguing that the primary investigator was not kept out of the loop of important study decisions. Heartwire
|
|
|
